KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulgent Genetics (FLGT) Deferred Taxes (2016 - 2025)

Fulgent Genetics' Deferred Taxes history spans 9 years, with the latest figure at -$104000.0 for Q4 2025.

  • For Q4 2025, Deferred Taxes rose 71.43% year-over-year to -$104000.0; the TTM value through Dec 2025 reached -$1.2 million, up 67.51%, while the annual FY2025 figure was -$1.2 million, 67.51% up from the prior year.
  • Deferred Taxes for Q4 2025 was -$104000.0 at Fulgent Genetics, up from -$864000.0 in the prior quarter.
  • Across five years, Deferred Taxes topped out at $19.4 million in Q3 2023 and bottomed at -$5.5 million in Q1 2022.
  • The 5-year median for Deferred Taxes is -$825000.0 (2021), against an average of -$497600.0.
  • The largest annual shift saw Deferred Taxes crashed 599.36% in 2022 before it surged 616.52% in 2023.
  • A 5-year view of Deferred Taxes shows it stood at -$1.6 million in 2021, then tumbled by 107.31% to -$3.3 million in 2022, then soared by 115.0% to $502000.0 in 2023, then plummeted by 172.51% to -$364000.0 in 2024, then surged by 71.43% to -$104000.0 in 2025.
  • Per Business Quant, the three most recent readings for FLGT's Deferred Taxes are -$104000.0 (Q4 2025), -$864000.0 (Q3 2025), and -$113000.0 (Q2 2025).